Summary
| Direction in Lyme Disease | ↑ Elevated — higher than in the comparison group |
|---|---|
| Category | Serologic |
| Also described as | IgG/IgM immunoblot band |
| Compared against | Uninfected |
| Associated symptoms | Common immunoblot band |
| Test type | Blood test (serum / plasma / whole blood) |
| Source | CDC 2024 — doi:10.1016/j.idc.2021.05.001 |
| Condition atlas | Lyme Disease Biomarker Atlas |
Related Serologic markers in Lyme Disease
- Anti-OspA antibodies ↑
- Anti-OspC antibodies ↑
- Anti-VlsE antibodies ↑
- C6 peptide ELISA (VisE) ↑
- IgM immunoblot (≥2 of 3 bands) ↑
- IgG immunoblot (≥5 of 10 bands) ↑
- B. burgdorferi EIA (screening) ↑
- Synovial fluid anti-Bb antibodies ↑
Full list: Lyme Disease Biomarker Atlas.
Frequently asked questions
Is Anti-p41 (flagellin) antibodies high or low in Lyme Disease?
Elevated. Studies summarised in the OSMF atlas report higher Anti-p41 (flagellin) antibodies in Lyme Disease than in Uninfected. Source: CDC 2024.
What symptoms is Anti-p41 (flagellin) antibodies associated with in Lyme Disease?
The cited literature associates this marker with Common immunoblot band. These are population-level associations and do not mean the marker causes the symptoms.
Which test measures Anti-p41 (flagellin) antibodies?
It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.
Is one abnormal Anti-p41 (flagellin) antibodies result diagnostic of Lyme Disease?
No. No single biomarker is diagnostic of Lyme Disease. Anti-p41 (flagellin) antibodies findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.
Cite this page
Subscribe on Substack
Last reviewed: 2026-06-29 · Page generated from lyme.json · Browse: Lyme Disease atlas · Biomarker Index · All marker pages
Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.